Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024 17:00 ET | Travere Therapeutics, Inc.
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at Upcoming Investor Conferences
February 26, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming investor conferences in...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024 16:01 ET | Travere Therapeutics, Inc.
Received 459 new patient start forms (PSFs) for FILSPARI® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S....
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 08, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15,...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 08, 2024 07:00 ET | Travere Therapeutics, Inc.
Received 459 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2023; preliminary net product sales of FILSPARI totaled $15 million for the fourth quarter Company on track to...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 42nd Annual...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023 16:01 ET | Travere Therapeutics, Inc.
          Received 430 new patient start forms for FILSPARI® (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow             Net product sales of FILSPARI totaled...
Travere-TxTM-Inline-fullcolor.png
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 24, 2023 16:30 ET | Travere Therapeutics, Inc.
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the...